Hematogenous histoplasmosis in the immunocompromised child

Walter T. Hughes

Research output: Contribution to journalArticle

Abstract

Hematogenous (disseminated) histoplasmosis occurred in 31 of 4158 children with cancer or immune deficiency disorders. Approximately half of the 31 patients had pulmonary lesions, reacted to the histoplasmin skin test, and generated complement-fixing antibodies to Histoplasma capsulatum. In a comparative study delayed hypersensitivity to histoplasmin was demonstrated in 36 (5.7%) of 634 children at the time of diagnosis of cancer. Patients with cancer who were reactive to histoplasmin before treatment were at no greater, and possibly less, risk for hematogenous histoplasmosis than were nonreactors. All of the 27 patients who received treatment for >1 day recovered; three had recurrences that responded to treatment.

Original languageEnglish (US)
Pages (from-to)569-575
Number of pages7
JournalJournal of Pediatrics
Volume105
Issue number4
DOIs
StatePublished - 1984
Externally publishedYes

Fingerprint

Histoplasmin
Histoplasmosis
Histoplasma
Neoplasms
Immune System Diseases
Delayed Hypersensitivity
Skin Tests
Therapeutics
Recurrence
Lung
Antibodies

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Hematogenous histoplasmosis in the immunocompromised child. / Hughes, Walter T.

In: Journal of Pediatrics, Vol. 105, No. 4, 1984, p. 569-575.

Research output: Contribution to journalArticle

Hughes, Walter T. / Hematogenous histoplasmosis in the immunocompromised child. In: Journal of Pediatrics. 1984 ; Vol. 105, No. 4. pp. 569-575.
@article{c6edc5fcb365490a8c51e31ad68c7fe3,
title = "Hematogenous histoplasmosis in the immunocompromised child",
abstract = "Hematogenous (disseminated) histoplasmosis occurred in 31 of 4158 children with cancer or immune deficiency disorders. Approximately half of the 31 patients had pulmonary lesions, reacted to the histoplasmin skin test, and generated complement-fixing antibodies to Histoplasma capsulatum. In a comparative study delayed hypersensitivity to histoplasmin was demonstrated in 36 (5.7{\%}) of 634 children at the time of diagnosis of cancer. Patients with cancer who were reactive to histoplasmin before treatment were at no greater, and possibly less, risk for hematogenous histoplasmosis than were nonreactors. All of the 27 patients who received treatment for >1 day recovered; three had recurrences that responded to treatment.",
author = "Hughes, {Walter T.}",
year = "1984",
doi = "10.1016/S0022-3476(84)80421-7",
language = "English (US)",
volume = "105",
pages = "569--575",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Hematogenous histoplasmosis in the immunocompromised child

AU - Hughes, Walter T.

PY - 1984

Y1 - 1984

N2 - Hematogenous (disseminated) histoplasmosis occurred in 31 of 4158 children with cancer or immune deficiency disorders. Approximately half of the 31 patients had pulmonary lesions, reacted to the histoplasmin skin test, and generated complement-fixing antibodies to Histoplasma capsulatum. In a comparative study delayed hypersensitivity to histoplasmin was demonstrated in 36 (5.7%) of 634 children at the time of diagnosis of cancer. Patients with cancer who were reactive to histoplasmin before treatment were at no greater, and possibly less, risk for hematogenous histoplasmosis than were nonreactors. All of the 27 patients who received treatment for >1 day recovered; three had recurrences that responded to treatment.

AB - Hematogenous (disseminated) histoplasmosis occurred in 31 of 4158 children with cancer or immune deficiency disorders. Approximately half of the 31 patients had pulmonary lesions, reacted to the histoplasmin skin test, and generated complement-fixing antibodies to Histoplasma capsulatum. In a comparative study delayed hypersensitivity to histoplasmin was demonstrated in 36 (5.7%) of 634 children at the time of diagnosis of cancer. Patients with cancer who were reactive to histoplasmin before treatment were at no greater, and possibly less, risk for hematogenous histoplasmosis than were nonreactors. All of the 27 patients who received treatment for >1 day recovered; three had recurrences that responded to treatment.

UR - http://www.scopus.com/inward/record.url?scp=0021172206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021172206&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(84)80421-7

DO - 10.1016/S0022-3476(84)80421-7

M3 - Article

C2 - 6090628

AN - SCOPUS:0021172206

VL - 105

SP - 569

EP - 575

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 4

ER -